CSL (ASX:CSL) Is Up 24.5% After Posting a Net Loss but Guiding for NPAT Growth - What's Changed

• In August 2026, CSL Limited reported full-year results showing revenue rising slightly to US$15.80 billion but moving from prior net income to a US$2.58 billion net loss, while also declaring a US$1.62 per share dividend for the six months ended June 30, 2026, payable on October 2, 2026.
• At the same time, CSL issued 2027 guidance calling for revenue to remain in line with the prior year but underlying NPAT to increase by about 5%, highlighting a contrast between current headline losses and management’s focus on adjusted earnings performance.
• We’ll now examine how CSL’s swing to a reported net loss alongside guidance for underlying NPAT growth shapes its broader investment narrative.

Uncover the next big thing with 56 elite penny stocks that balance risk and reward.

What Is CSL's Investment Narrative?

To own CSL today, you really need to believe its plasma, rare disease and vaccine franchises can translate modest top-line growth into improving underlying profitability, despite a headline loss. The swing to a US$2.58 billion net loss on roughly flat revenue, paired with guidance for around 5% growth in underlying NPAT in 2027, puts the quality and sustainability of “underlying” earnings at the centre of the story. The new dividend of US$1.62 per share suggests management wants to signal confidence in cash generation, even as reported earnings are under pressure. Near term, key catalysts still sit around execution in core plasma therapies and progress in products like ANDEMBRY and HEMGENIX, but the loss and high debt load sharpen the focus on balance sheet resilience and the risk of further write downs or restructuring. Recent sharp share price gains hint that much of this news may already be partially reflected in expectations, yet the gap between reported and adjusted results now feels like a more immediate issue for shareholders to weigh.

However, that gap between reported losses and “underlying” profit is something investors should understand. CSL's shares have been on the rise but are still potentially undervalued by 21%. Find out what it's worth.

Exploring Other Perspectives

Fourteen Simply Wall St Community fair values span roughly US$108 to US$240 per share, reflecting very different expectations around CSL’s earnings recovery. Set these views against the recent swing to a multi billion dollar net loss and management’s focus on underlying NPAT, and you can see why it pays to compare several perspectives before forming a view on the company’s prospects.

Explore 14 other fair value estimates on CSL - why the stock might be worth as much as 40% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CSL research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.